Stock Events

Stock Events

Gubra AS 

€44.98
0
-€0.46-1.01% Friday 19:55

Statistics

Day High
46.54
Day Low
44.88
52W High
74.05
52W Low
43.64
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27FebExpected
Q4 2025
-0.58
-0.39
-0.2
-0.01
Expected EPS
-0.007967068200000002
Actual EPS
-0.5842516680000001

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PI3.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap164.13B
Novo Nordisk is a leading global healthcare company specializing in diabetes care, which directly competes with Gubra's focus on obesity and diabetes research.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly is a major player in the pharmaceutical industry with significant investments in diabetes and metabolic disorders, overlapping with Gubra's research areas.
Sanofi
SNY
Mkt Cap116.63B
Sanofi operates globally in the pharmaceutical sector, focusing on chronic diseases including diabetes, competing in the same therapeutic areas as Gubra.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca actively develops treatments for various metabolic disorders, including diabetes, positioning it as a competitor in the same field as Gubra.
Merck
MRK
Mkt Cap298.84B
Merck is known for its strong portfolio in diabetes care and treatment, making it a direct competitor to Gubra's diabetes-related projects.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb, with its broad range of biopharmaceutical products, competes in the metabolic disease sector, relevant to Gubra's focus areas.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a diverse portfolio that includes treatments for metabolic disorders and diabetes, competing with Gubra in these healthcare segments.
Roche
RHHBY
Mkt Cap321.08B
Roche, with its extensive research and development in diabetes management and other metabolic disorders, is a competitor in the same scientific space as Gubra.
Takeda Pharmaceutical
TAK
Mkt Cap59.2B
Takeda focuses on lifestyle and chronic diseases, including diabetes, which aligns them as competitors with Gubra in the field of metabolic health research.

About

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology. It also has a portfolio strategy of potential drug candidates in the form of upfront payments, research payments, milestone payments, and royalties; and investments targeting as sets promoting the green transition. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Camurus' FluidCrystal technology to develop a therapy for hypoparathyroidism; Amylyx Pharmaceuticals to develop a GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is headquartered in Horsholm, Denmark.
Show more...
CEO
Mr. Markus Rohrwild Ph.D.
Employees
300
Country
Denmark
ISIN
DK0062266474

Listings

STU
DE
PI3.STU
MU
DE
PI3.MU
OTC Link
US
GUBRF
CO
DK
GUBRA.CO

0 Comments

Share your thoughts

FAQ

What is Gubra AS stock price today?▼
The current price of PI3.STU is €44.98 EUR — it has decreased by -1.01% in the past 24 hours. Watch Gubra AS stock price performance more closely on the chart.
What is Gubra AS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Gubra AS stocks are traded under the ticker PI3.STU.
Is Gubra AS stock price growing?▼
PI3.STU stock has fallen by -6.99% compared to the previous week, the month change is a -8.58% fall, over the last year Gubra AS has showed a -10.4% decrease.
When is the next Gubra AS earnings date?▼
Gubra AS is going to release the next earnings report on August 20, 2026.
What were Gubra AS earnings last quarter?▼
PI3.STU earnings for the last quarter are -0.58 EUR per share, whereas the estimation was -0.01 EUR resulting in a -7,233.33% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Gubra AS have?▼
As of April 12, 2026, the company has 300 employees.
In which sector is Gubra AS located?▼
Gubra AS operates in the Health & Wellness sector.
When did Gubra AS complete a stock split?▼
Gubra AS has not had any recent stock splits.
Where is Gubra AS headquartered?▼
Gubra AS is headquartered in Horsholm, Denmark.